Roivant Sciences Ltd. (ROIV) |
|
6.92 -0.07 (-1%)
|
03-24 16:00 |
|
Open: |
6.99 |
Pre. Close: |
6.99 |
|
High:
|
7.05 |
Low:
|
6.65 |
|
Volume:
|
5,320,409 |
Market Cap:
|
5,248(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:29:25 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 9.38 One year: 10.43 |
| Support: |
Support1: 6.58 Support2: 5.47 |
| Resistance: |
Resistance1: 8.03 Resistance2: 8.93 |
| Pivot: |
7.91  |
| Moving Average: |
MA(5): 7.5 MA(20): 7.94
MA(100): 7.35  MA(250): 5.34 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 10.6 %D(3): 17.4 |
| RSI: |
RSI(14): 35 |
| 52-week: |
High: 10 Low: 2.51 |
| Average Vol(K): |
3-Month: 2,845 (K) 10-Days: 5,060 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ROIV ] has closed above bottom band by 5.5%. Bollinger Bands are 20% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.06 - 7.11 |
7.11 - 7.15 |
|
Low:
|
6.53 - 6.59 |
6.59 - 6.64 |
|
Close:
|
6.83 - 6.92 |
6.92 - 6.99 |
|
Company Description |
|
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom. |
Headline News |
Mon, 27 Mar 2023
What Recent Market Trends Mean for Roivant Sciences Ltd.'s (ROIV ... - The News Heater
Fri, 24 Mar 2023
Svf Investments (Uk) Ltd Sells 12000000 Shares of Roivant ... - Defense World
Thu, 23 Mar 2023
Is Roivant Sciences Ltd (ROIV) Stock a Smart Investment Thursday? - InvestorsObserver
Tue, 21 Mar 2023
12 Best Biotech Stocks To Buy Under $20 - Yahoo Finance
Fri, 17 Mar 2023
Can Roivant Sciences Ltd (ROIV) Stock Rise to the Top of Healthcare Sector Friday? - InvestorsObserver
Thu, 16 Mar 2023
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
725 (M) |
|
% Held by Insiders
|
1.6214e+008 (%) |
|
% Held by Institutions
|
50.4 (%) |
|
Shares Short
|
16,400 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
99 |
|
Return on Equity (ttm)
|
-24.9 |
|
Qtrly Rev. Growth
|
5.042e+007 |
|
Gross Profit (p.s.)
|
-8.26 |
|
Sales Per Share
|
-50.73 |
|
EBITDA (p.s.)
|
-3.28421e+008 |
|
Qtrly Earnings Growth
|
-4.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-858 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.14 |
|
Price to Cash Flow
|
2.92 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.283e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
